Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302

医学 内科学 多西紫杉醇 化疗 子群分析 外科肿瘤学 胃肠病学 不利影响 肿瘤科 外科 置信区间
作者
Hiroki Hara,Taroh Satoh,Takashi Kojima,Takahiro Tsushima,Yu Sunakawa,Morihito Okada,Ningning Ding,Hongzhen Wu,Liyun Li,Yu Tian,Gisoo Barnes,Ken Kato
出处
期刊:Esophagus [Springer Science+Business Media]
卷期号:21 (2): 102-110
标识
DOI:10.1007/s10388-023-01040-w
摘要

Esophageal squamous cell carcinoma (ESCC) has a poor prognosis, with limited second-line systemic therapy options, and represents an increasing disease burden in Japan. In the phase 3 RATIONALE-302 study, the anti-programmed cell death protein 1 antibody, tislelizumab, significantly improved overall survival (OS) versus chemotherapy as second-line treatment for advanced/metastatic ESCC. Here, we report the Japanese patient subgroup results.Patients with advanced/metastatic ESCC, with disease progression during/after first-line systemic therapy were randomized 1:1 to open-label tislelizumab 200 mg every 3 weeks or investigator's choice of chemotherapy (paclitaxel/docetaxel). Efficacy and safety were assessed in all randomized Japanese patients.The Japanese subgroup comprised 50 patients (n = 25 per arm). Tislelizumab improved OS versus chemotherapy (median: 9.8 vs. 7.6 months; HR 0.59; 95% CI 0.31, 1.12). Among patients with programmed death-ligand 1 score ≥ 10%, median OS was 12.5 months with tislelizumab (n = 10) versus 2.9 months with chemotherapy (n = 6) (HR 0.31; 95% CI 0.09, 1.03). Tislelizumab improved progression-free survival versus chemotherapy (median: 3.6 vs. 1.7 months, respectively; HR 0.50; 95% CI 0.27, 0.95). Objective response rate was greater with tislelizumab (32.0%) versus chemotherapy (20.0%), and responses were more durable (median duration of response: 8.8 vs. 2.6 months, respectively). Fewer patients experienced ≥ grade 3 treatment-related adverse events with tislelizumab (24.0%) versus chemotherapy (47.8%). Tislelizumab demonstrated an improvement in health-related quality of life versus chemotherapy.As second-line therapy for advanced/metastatic ESCC, tislelizumab improved OS versus chemotherapy, with a favorable safety profile, in the Japanese patient subgroup, consistent with the overall population.ClinicalTrials.gov: NCT03430843.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
初醒完成签到,获得积分10
刚刚
P1atinum发布了新的文献求助10
1秒前
从容的雪碧完成签到,获得积分10
1秒前
1秒前
zjx完成签到,获得积分20
1秒前
全或无完成签到,获得积分10
2秒前
化学完成签到 ,获得积分10
2秒前
九月完成签到,获得积分10
2秒前
酷波er的应助被77采纳,获得10
2秒前
WangWaud完成签到,获得积分10
2秒前
热情曲奇完成签到,获得积分10
3秒前
张张张发布了新的文献求助30
3秒前
思源的应助被GBY采纳,获得10
3秒前
爱撒娇的蝴蝶完成签到 ,获得积分10
3秒前
galioo3000发布了新的文献求助10
3秒前
留胡子的藏鸟完成签到,获得积分10
3秒前
老迟到的涫完成签到,获得积分10
3秒前
cancanwode完成签到,获得积分10
4秒前
4秒前
郑梅梅完成签到,获得积分10
4秒前
Mia完成签到,获得积分10
4秒前
哎呀发布了新的文献求助10
4秒前
朴实的之桃完成签到,获得积分10
4秒前
33月完成签到 ,获得积分10
4秒前
空城完成签到,获得积分10
4秒前
jiqipek完成签到,获得积分10
4秒前
传奇3的应助被tomosun1996采纳,获得10
5秒前
GAOYUwenzhang完成签到,获得积分10
5秒前
听汐完成签到 ,获得积分10
5秒前
5秒前
牛马发布了新的文献求助10
5秒前
牛马发布了新的文献求助10
5秒前
6秒前
牛马发布了新的文献求助10
6秒前
佳佳完成签到,获得积分10
6秒前
敏敏完成签到,获得积分10
7秒前
英俊的铭的应助被Linz采纳,获得10
7秒前
Q米嘛氏Q完成签到,获得积分10
7秒前
舒服的笑旋完成签到,获得积分10
7秒前
溜野完成签到,获得积分20
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8167057
求助须知:如何正确求助?哪些是违规求助? 9559880
关于积分的说明 21753012
捐赠科研通 7757815
什么是DOI,文献DOI怎么找? 3429221
关于科研通互助平台的介绍 2553594
邀请新用户注册赠送积分活动 2473967